Clinical trials: Otorhinolaryngologic Neoplasms
Nasopharyngeal Carcinoma
Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage
Up to now, IMRT has largely improved the local control of locally advanced nasopharyngeal carcinoma (NPC), leaves the distant metastasis as the main treatment failure modality of patients with bulky lymph nodes (especially N3…
- Trial name
- NCT03403829
- Testing
- Gemcitabine, standard chemoradiotherapy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Fudan University
Vestibular Schwannoma, Hearing Loss
Intraoperative EABR for Decision Making
In this study patients undergoing simultaneous translabyrinthine vestibular schwannoma resection and cochlear implantation are included. The goal of the study is to correlate the eABR results with postoperative hearing results.
- Trial name
- NCT03745560
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Christoph Arnoldner
Head and Neck Neoplasms, Laryngeal Neoplasms
Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
BACKGROUND: Concomitant radiotherapy and cisplatin (CDDP) based chemotherapy is the standard treatment for LA-NHSCC. This combined modality treatment is linked with considerable acute local and systemic toxicity.EGFR is…
- Conditions
- Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Pharyngeal Neoplasms
- Trial name
- CTXMAB+RT (NCT01216020)
- Testing
- cetuximab, cisplatin (associated to radiotherapy)
- Where
- 7 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Azienda USL 4 Prato
Locally Advanced Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma
In this study, the investigators aim to compare the progression-free survival (PFS) and side effects of radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients…
- Trial name
- IRCNPC (NCT03015727)
- Testing
- Docetaxel, Cisplatin, IMRT/TOMO
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue
The investigators collect nasopharyngeal epithelium samples from healthy individuals and analyze for biomarkers compared with tumor tissues from another clinical research project.
- Trial name
- NCT03048305
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Presbylarynx, Aspiration
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders.
- Conditions
- Presbylarynx, Aspiration, Spasmodic Dysphonia, Globus Pharyngeus
- Trial name
- NCT06078527
- Testing
- Cheung-Bearelly Aesthesiometer, Transnasal Laryngoscopy, Questionnaires
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Nasopharyngeal Carcinoma
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally advanced NPC.
- Trial name
- NCT02012062
- Testing
- TPF neoadjuvant chemotherapy, Concurrent chemotherapy with cisplatin during radiotherapy, Concurrent nimotuzumab during radiotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Oropharynx Cancer
Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME)
Standard treatment for oropharynx cancer is radiotherapy by intensity modulation with only one planification before treatment. Adaptative radiotherapy integrates one or several planifications during treatment radiotherapy in…
- Trial name
- ARTOME (NCT05025618)
- Where
- 11 sites in France
- Volunteers
- 132 people
- Sponsor
- Center Eugene Marquis
Head and Neck Cancer
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants with unresectable locally advanced…
- Trial name
- NCT06056310
- Testing
- Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 18 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Nasopharyngeal Neoplasms
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
In an effort to identify genetic factors linked to the development of nasopharyngeal cancer (NPC), the researchers identified and sampled 2,394 individuals from Taiwanese families in which two or more relatives had been diagnosed…
- Trial name
- NCT00393224
- Where
- China
- Volunteers
- 952 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Reactivating NK Cells in Treating Refractory Head and Neck Cancer
This study aims to determine the safety and efficacy of expanded activated autologous NK cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or head and neck squamous cell carcinoma.
- Trial name
- NKEXPHNC (NCT02507154)
- Testing
- Cetuximab + NK cells
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma
The study is to observe the efficacy and toxicity of demethylating drug decitabine and cisplatin induced chemotherapy for 3 cycles followed by concurrent chemoradiotherapy in the treatment of regionally advanced nasopharyngeal…
- Trial name
- NCT03701451
- Testing
- Demethylated drug decitabine
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Wei Jiang
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT06029270
- Testing
- Biospecimen Collection, Bone Scan, Carboplatin
- Where
- 95 sites in United States, Australia and 3 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Myasthenia Gravis, Guillain-Barre Syndrome
Neurology Inpatient Clinical Education Trial
The objective of this study is to compare the effectiveness of a personalized patient education program to the current hospital education and evaluate its impact using patient satisfaction scores.
- Conditions
- Myasthenia Gravis, Guillain-Barre Syndrome, Multiple Sclerosis, Seizures
- Trial name
- NCT03826056
- Testing
- Current standard discharge educational intervention, Personalized discharge educational intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Head and Neck Cancer, Pharynx Cancer
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
Radiotherapy (RT) with concurrent chemotherapy represents the state of the art in curative intent treatment for locally advanced squamous carcinoma of the head and neck.
- Trial name
- NCT00140556
- Testing
- Chemoradiotherapy, Cisplatin, Bevacizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- David M. Brizel, MD
Renal Cell Carcinoma, Nasopharyngeal Carcinoma
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.
- Conditions
- Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
- Trial name
- NCT05721222
- Testing
- GEN1160
- Where
- 17 sites in United States, China
- Volunteers
- 42 people
- Sponsor
- Genmab
Oropharyngeal Cancer
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
More and more studies have shown that the efficacy and prognosis of HPV （Human papillomavirus）-positive oropharyngeal cancer (OPC) patients are better than those of others.
- Trial name
- NCT06156891
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Esophageal Cancer
Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia
Hypothesis: In the management of advanced oesophageal cancer, to determine if a shorter regime of external beam radiotherapy (using higher daily doses, and combined with intraluminal high dose rate brachytherapy) is not inferior…
- Trial name
- NCT00665197
- Testing
- Protracted Course Radiotherapy, Short Course Radiotherapy
- Where
- 7 sites in Canada, China and 5 more
- Volunteers
- 200 people
- Sponsor
- International Atomic Energy Agency